OncoMatch/Clinical Trials/NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Is NCT03970447 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for glioblastoma.
Treatment: Temozolomide · Lomustine · Regorafenib · Paxalisib · VAL-083 · VT1021 · Troriluzole · ADI-PEG 20 · AZD1390 — Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage GRADE IV (WHO)
Grade: IV (WHO)
Grade IV GBM, inclusive of gliosarcoma (WHO criteria; IDH wild-type by immunohistochemistry [IHC] or sequencing for IDH)
Prior therapy
Must have received: radiation therapy — recurrent
at first or second recurrence after initial standard, control or experimental therapy that includes at a minimum radiation therapy (RT)
Cannot have received: prolifeprospan 20 with carmustine wafer (prolifeprospan 20 with carmustine wafer)
Prior prolifeprospan 20 with carmustine wafer
Cannot have received: intracerebral, intratumoral, or cerebral spinal fluid (CSF) agent
Prior intracerebral, intratumoral, or cerebral spinal fluid (CSF) agent
Cannot have received: radiation therapy
Prior radiation treatment for GBM or lower-grade glioma
Cannot have received: chemotherapy
Prior chemotherapy or immunotherapy for GBM or lower-grade glioma
Cannot have received: immunotherapy
Prior chemotherapy or immunotherapy for GBM or lower-grade glioma
Cannot have received: lomustine (lomustine)
Received any prior treatment with lomustine
Cannot have received: bevacizumab or other vascular endothelial growth factor (VEGF) or VEGF receptor-mediated targeted agent (bevacizumab)
bevacizumab or other vascular endothelial growth factor (VEGF) or VEGF receptor-mediated targeted agent
Lab requirements
Cardiac function
qtc > 450 msec if male and qtc > 470 msec if female [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California, San Diego · La Jolla, California
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute · Los Angeles, California
- University of California, Los Angeles · Los Angeles, California
- St. Joseph Hospital · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify